MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study - PubMed (original) (raw)
MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study
C McManus et al. J Neuroimmunol. 1998.
Abstract
Chemokines are low molecular weight chemotactic cytokines that have been shown to play a central role in the perivascular transmigration and accumulation of specific subsets of leukocytes at sites of tissue damage. Two major families have been defined depending on the positioning of four conserved cysteines. The CXC chemokines predominantly attract neutrophils, whereas the CC chemokines predominantly attract monocytes and other leukocyte cell types. Members of the monocyte chemotactic protein (MCP)-1 family form a major component of the CC family of chemokines and are considered the principal chemokines involved in the recruitment of monocytes/macrophages and activated lymphocytes. In this study we addressed the expression and distribution of MCP-1, -2 and -3 in multiple sclerosis (MS) lesions of differing ages and levels of inflammatory activity using immunohistochemistry and in situ hybridization. In acute and chronic-active MS lesions immunoreactivity for MCP-1, -2 and -3 was prominent throughout the lesion center with reactivity diminishing abruptly at the lesion edge. Hypertrophic astrocytes were strongly reactive and inflammatory cells showed variable reactivity. Outside of the lesion only hypertrophic astrocytes were reactive. The results obtained by in situ hybridization for MCP-1 were in agreement with those obtained by immunostaining. In more chronic lesions immunoreactivity for MCP-1, -2 and -3 was considerably diminished, and in chronic-silent lesions immunoreactivity was restricted to a few scattered reactive astrocytes. Normal control brains showed no immunoreactivity for MCP-1, -2 and -3. Although the cellular distribution of all three members of this family was similar, antibodies to MCP-3 gave prominent staining of the extracellular matrix that was not noted for MCP-1 and -2. These results support the conclusion that members of the MCP family of chemokines are involved in the development of MS lesions in the central nervous system.
Similar articles
- Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions.
Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Simpson JE, et al. J Neuroimmunol. 1998 Apr 15;84(2):238-49. doi: 10.1016/s0165-5728(97)00208-7. J Neuroimmunol. 1998. PMID: 9628469 - Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue.
Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN. Simpson J, et al. J Neuroimmunol. 2000 Aug 1;108(1-2):192-200. doi: 10.1016/s0165-5728(00)00274-5. J Neuroimmunol. 2000. PMID: 10900353 - A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein.
Calderon TM, Eugenin EA, Lopez L, Kumar SS, Hesselgesser J, Raine CS, Berman JW. Calderon TM, et al. J Neuroimmunol. 2006 Aug;177(1-2):27-39. doi: 10.1016/j.jneuroim.2006.05.003. Epub 2006 Jun 19. J Neuroimmunol. 2006. PMID: 16782208 - Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1.
Proost P, Wuyts A, Van Damme J. Proost P, et al. J Leukoc Biol. 1996 Jan;59(1):67-74. doi: 10.1002/jlb.59.1.67. J Leukoc Biol. 1996. PMID: 8558070 Review. - Chemokines, a family of chemotactic cytokines.
Graves DT, Jiang Y. Graves DT, et al. Crit Rev Oral Biol Med. 1995;6(2):109-18. doi: 10.1177/10454411950060020101. Crit Rev Oral Biol Med. 1995. PMID: 7548618 Review.
Cited by
- Microglia Colonization Associated with Angiogenesis and Neural Cell Development.
Harry GJ. Harry GJ. Adv Neurobiol. 2024;37:163-178. doi: 10.1007/978-3-031-55529-9_10. Adv Neurobiol. 2024. PMID: 39207692 Review. - Blood-based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
Wei Q, Li J, Zhao C, Meng S, Liu N, Wu Z, Liu F, Cui L, Hu W, Zhao Y. Wei Q, et al. CNS Neurosci Ther. 2024 Jun;30(6):e14811. doi: 10.1111/cns.14811. CNS Neurosci Ther. 2024. PMID: 38923840 Free PMC article. - Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study.
Akter M, Roknuzzaman ASM, Shahriar M, Islam SMA, Ahmed Bhuiyan M, Qusar MMAS, Kabir ER, Islam R. Akter M, et al. PLoS One. 2024 Jun 18;19(6):e0305734. doi: 10.1371/journal.pone.0305734. eCollection 2024. PLoS One. 2024. PMID: 38889138 Free PMC article. - Evaluating CXCL12 for Effects on Reactive Gene Expression in Primary Astrocytes.
Zieger K, Cao C, Engele J. Zieger K, et al. J Mol Neurosci. 2024 May 28;74(2):57. doi: 10.1007/s12031-024-02231-5. J Mol Neurosci. 2024. PMID: 38802573 - Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
Harris VK, Stark J, Williams A, Roche M, Malin M, Kumar A, Carlson AL, Kizilbash C, Wollowitz J, Andy C, Gerber LM, Sadiq SA. Harris VK, et al. Stem Cell Res Ther. 2024 May 23;15(1):151. doi: 10.1186/s13287-024-03765-6. Stem Cell Res Ther. 2024. PMID: 38783390 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous